"Glenmark Pharmaceuticals Inc., USA (Glenmark), a research-led, global pharmaceutical company, announces the launch of vancomycin hydrochloride for injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (single-dose vial). Glenmark’s vancomycin hydrochloride for injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (single-dose vial) is bioequivalent and therapeutically equivalent to the reference listed drug, vancomycin hydrochloride for injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial of Mylan Laboratories Limited, NDA 209481.
According to IQVIA sales data for the 12-month period ending January 2025, the vancomycin hydrochloride for injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (single-dose vial) market achieved annual sales of approximately $39.3 million.
Commenting on the launch, Marc Kikuchi, president & business head, North America said, “We are excited to announce the launch of vancomycin hydrochloride for injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (single-dose vial), adding another quality product to our institutional portfolio.”
Glenmark Pharmaceuticals Ltd. is a research-led, global pharmaceutical company, having a presence across branded, generics, and OTC segments; with a focus on therapeutic areas of cardio-metabolic, respiratory, dermatology and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries."